牛皮癬治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球牛皮癬治療市場價值為 281 億美元，預計到 2034 年將以 9.4% 的複合年成長率成長至 684 億美元。

這一上升趨勢的動力源於全球自體免疫性皮膚病和慢性發炎性疾病發病率的不斷上升。醫療保健提供者和患者意識的不斷增強，加上新一代生物製劑和標靶小分子藥物的不斷發展，持續推動市場的發展。個人化治療方法和先進藥物傳輸技術的新興創新也在加速市場成長方面發揮重要作用。隨著慢性皮膚病負擔的加重，對有效、便利且永續治療方案的需求正在迅速成長。該行業不斷發展，擁有多樣化的治療方案，專注於改善患者預後、最大程度地減少疾病發作並提高整體生活品質。個人化醫療解決方案需求的成長以及整個製藥業研發活動的加強也促進了該市場的持續擴張。

斑塊癬和乾癬性關節炎是該疾病最常見的表現形式，許多患者會感到關節不適，這增加了對全身性治療方法的需求。乾癬治療市場屬於皮膚病學和免疫學領域，專注於治療這種以發炎、鱗狀病變和全身症狀為特徵的長期免疫驅動性皮膚病。廣泛的治療選擇定義了該領域，從皮質類固醇和維生素D類似物等外用溶液，到IL-17、TNF-α和IL-23抑製劑等口服藥物和注射生物製劑，包括旨在實現經濟有效的治療可及性的生物類似藥。

2024年，皮質類固醇因其標靶作用機制和成熟的臨床療效，佔37.4%的市場。預計到2034年，該細分市場的規模將達到252億美元，複合年成長率為9.2%。皮質類固醇因其價格實惠、療效持久和症狀緩解迅速等特點而廣泛應用。皮質類固醇憑藉其抗發炎和免疫調節的雙重特性，仍然是輕度至中度疾病的首選治療方案，尤其是在門診治療中。

2024年，局部治療領域收入達到156億美元，這得益於其易用性和較低的全身性副作用風險。局部治療仍然是症狀較輕患者的第一道防線，通常在治療初期或長期疾病管理中使用。這些劑型包括乳膏、泡沫和凝膠等，經濟高效且使用方便，非常適合日常常規使用。

2024年，北美銀屑病治療市場佔據41.1%的市場。不斷成長的病例數量以及對研發驅動型產品開發的雄厚資金支持推動了該地區的成長。堅實的醫療保健框架支持該地區各國對早期疾病的發現和及時干預。大型製藥商的入駐推動了皮膚科藥物、生物相似藥的上市以及口服治療方案的創新。同時，優惠的保險政策和公共衛生運動正在改善患者獲得先進治療方案的管道。

影響牛皮癬治療市場的關鍵參與者包括強生、輝瑞、默克、Biogen、艾伯維、禮來、Biocon、利奧製藥、安進、諾華、UCB Pharma、Arcutis Biotherapeutics、勃林格殷格翰、太陽製藥和百時美施貴寶。這些公司繼續引領市場創新、臨床試驗和治療進步。在牛皮癬治療市場中運作的公司正在採取多種策略來擴大其影響力和競爭優勢。主要工作包括優先研發具有更高療效和更少副作用的生物製劑和小分子藥物。許多公司正在積極擴展其藥物管線，開發針對 IL 和 TNF 途徑的下一代治療方法。此外，還在尋求策略合作夥伴關係、收購和授權交易，以加速創新和進入新的區域市場。人們越來越關注生物相似藥，以提高可負擔性和治療的可及性。

目錄

第1章：方法論與範圍

第 2 章：執行摘要

第3章：行業洞察

• 產業生態系統分析
  • 供應商格局
  • 每個階段的增值
  • 影響價值鏈的因素
• 產業衝擊力
  • 成長動力
    • 牛皮癬盛行率不斷上升
    • 人口結構變化與遺傳風險因素
    • 下一代療法的出現
    • 更加關注全身性發炎和合併症
  • 產業陷阱與挑戰
    • 治療相關併發症和抗藥性
    • 醫療服務欠缺地區的醫療保健差距
  • 市場機會
    • 標靶治療和聯合治療方案的創新
    • 精準皮膚病學和數位健康的發展
• 成長潛力分析
• 監管格局
  • 北美洲
  • 歐洲
  • 亞太地區
• 未來市場趨勢
• 投資和融資格局
• 管道分析
• 定價分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係與協作
  • 新產品發布
  • 擴張計劃

第5章：市場估計與預測：按藥物類別，2021 - 2034 年

• 主要趨勢
• 白血球介素抑制劑
  • 蘇金單抗
  • 烏司奴單抗
  • 其他白血球介素抑制劑
• TNF抑制劑
  • 依那西普
  • 賽妥珠單抗
  • 阿達木單抗
  • 英夫利西單抗
  • 戈利木單抗
• 維生素D類似物
  • 骨化三醇
  • 卡泊三醇
  • 他卡西醇
• 皮質類固醇
• 其他藥物類別

第6章：市場估計與預測：按類型，2021 - 2034

• 主要趨勢
• 銀屑病關節炎
• 斑塊癬
• 逆向牛皮癬
• 其他類型

第7章：市場估計與預測：按管理路線，2021 - 2034 年

• 主要趨勢
• 口服
• 腸外
• 外用

第 8 章：市場估計與預測：按配銷通路，2021 年至 2034 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 其他分銷管道

第9章：市場估計與預測：按地區，2021 - 2034

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• AbbVie
• Amgen
• Arcutis Biotherapeutics
• Biocon
• Biogen
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Eli Lilly
• Johnson & Johnson
• LEO Pharma
• Merck & Co.
• Novartis
• Pfizer
• Sun Pharmaceutical
• UCB Pharma

The Global Psoriasis Treatment Market was valued at USD 28.1 billion in 2024 and is estimated to grow at a CAGR of 9.4% to reach USD 68.4 billion by 2034.

The upward trend is fueled by the growing incidence of autoimmune skin diseases and chronic inflammatory disorders worldwide. Increased awareness among both healthcare providers and patients, coupled with the continuous development of next-generation biologics and targeted small-molecule drugs, continues to push the market forward. Emerging innovations in personalized treatment approaches and advanced drug delivery technologies are also playing a major role in accelerating market growth. As the burden of chronic skin conditions grows, the demand for effective, accessible, and sustainable treatment options is expanding rapidly. The industry continues to evolve with a diverse pipeline of therapies that focus on improving patient outcomes, minimizing flare-ups, and enhancing overall quality of life. The rise in demand for personalized healthcare solutions and greater R&D activity across the pharmaceutical sector are also contributing to the ongoing expansion of this market.

Plaque psoriasis and psoriatic arthritis represent the most prevalent manifestations of the disease, with many patients experiencing joint discomfort that increases the demand for systemic treatment approaches. The psoriasis treatment market falls within the dermatology and immunology sectors, focusing on managing this long-term immune-driven skin disorder marked by inflamed, scaly lesions and systemic symptoms. A broad portfolio of therapeutic choices defines the space, ranging from topical solutions like corticosteroids and vitamin D analogs to oral agents and injectable biologics such as IL-17, TNF-a, and IL-23 inhibitors, including biosimilars designed for cost-effective treatment access.

In 2024, the corticosteroids segment accounted for a 37.4% share due to their targeted mechanism and well-established clinical outcomes. This segment is forecasted to reach USD 25.2 billion by 2034, at a CAGR of 9.2%. Their widespread use stems from affordability, consistent effectiveness, and rapid symptom relief. Corticosteroids remain a go-to solution for mild to moderate disease severity, particularly in outpatient care settings, thanks to their dual anti-inflammatory and immune-modulating properties.

The topical therapies segment generated USD 15.6 billion in 2024, driven by their ease of use and lower risk of systemic side effects. They remain the first line of defense for individuals with milder symptoms, often prescribed at the onset of treatment or for long-term disease management. These formulations, available in forms like creams, foams, and gels, offer cost-effective and user-friendly administration, making them highly favorable for routine application in everyday settings.

North America Psoriasis Treatment Market held 41.1% share in 2024. The regional growth is propelled by increasing case numbers and robust financial backing for research-driven product development. A solid healthcare framework supports early-stage disease detection and timely intervention across countries within the region. The presence of major pharmaceutical manufacturers has spurred innovation in dermatological medications, biosimilar launches, and oral therapeutic options. At the same time, beneficial insurance policies and public health campaigns are improving patient access to advanced treatment solutions.

Key players influencing the Psoriasis Treatment Market include Johnson & Johnson, Pfizer, Merck & Co., Biogen, AbbVie, Eli Lilly, Biocon, LEO Pharma, Amgen, Novartis, UCB Pharma, Arcutis Biotherapeutics, Boehringer Ingelheim, Sun Pharmaceutical, and Bristol-Myers Squibb. These companies continue to lead innovation, clinical trials, and therapeutic advancements within the market. Companies operating in the Psoriasis Treatment Market are adopting multiple strategies to expand their footprint and competitive edge. Key efforts include prioritizing R&D to develop biologics and small-molecule drugs with higher efficacy and reduced side effects. Many firms are actively expanding their drug pipelines with next-gen treatments targeting IL and TNF pathways. Strategic partnerships, acquisitions, and licensing deals are also being pursued to accelerate innovation and enter new regional markets. A growing focus is placed on biosimilars to enhance affordability and treatment accessibility.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumption and limitations

Chapter 2 Executive Summary

• 2.1 Industry 3600 synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Drug class trends
  • 2.2.3 Type trends
  • 2.2.4 Route of administration trends
  • 2.2.5 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of psoriasis
    • 3.2.1.2 Demographic shifts and hereditary risk factors
    • 3.2.1.3 Emergence of next-generation therapies
    • 3.2.1.4 Heightened focus on systemic inflammation and comorbidities
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Treatment-related complications and resistance
    • 3.2.2.2 Healthcare disparities in underserved regions
  • 3.2.3 Market opportunities
    • 3.2.3.1 Innovation in targeted and combination regimens
    • 3.2.3.2 Growth in precision dermatology and digital health
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Future market trends
• 3.6 Investment and funding landscape
• 3.7 Pipeline analysis
• 3.8 Pricing analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Interleukins inhibitors
  • 5.2.1 Secukinumab
  • 5.2.2 Ustekinumab
  • 5.2.3 Other interleukin inhibitors
• 5.3 TNF inhibitors
  • 5.3.1 Etanercept
  • 5.3.2 Certolizumab pegol
  • 5.3.3 Adalimumab
  • 5.3.4 Infliximab
  • 5.3.5 Golimumab
• 5.4 Vitamin D analogs
  • 5.4.1 Calcitriol
  • 5.4.2 Calcipotriol
  • 5.4.3 Tacalcitol
• 5.5 Corticosteroids
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Psoriatic arthritis
• 6.3 Plaque psoriasis
• 6.4 Inverse psoriasis
• 6.5 Other types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral
• 7.4 Topical

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AbbVie
• 10.2 Amgen
• 10.3 Arcutis Biotherapeutics
• 10.4 Biocon
• 10.5 Biogen
• 10.6 Boehringer Ingelheim
• 10.7 Bristol-Myers Squibb
• 10.8 Eli Lilly
• 10.9 Johnson & Johnson
• 10.10 LEO Pharma
• 10.11 Merck & Co.
• 10.12 Novartis
• 10.13 Pfizer
• 10.14 Sun Pharmaceutical
• 10.15 UCB Pharma